C4 Therapeutics rises after quarterly revenue beat
11/08/2026 14:44
BUZZ-C4 Therapeutics rises after quarterly revenue beat ** Shares of drug developer C4 Therapeutics CCCC.O rise 2.5% to $3.68
** Company's Q2 revenue of $6.6 million beats analysts' average expectation of $4 million
** C4 says the boost was primarily related to revenue recognized under the new collaboration agreement with Swiss drugmaker Roche ROPC.S
** The companies are partnering to create highly targeted cancer drugs, combining two different technologies to make a new kind of medicine called a Degrader-Antibody Conjugate
** C4 reports Q2 loss of 18 cents/share versus analysts' average loss estimate of 23 cents/share, according to LSEG data
** Including session's move, the stock up 89.5% YTD
(Reporting by Christy Santhosh)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey